ĐÁNH GIÁ MỘT SỐ TÁC DỤNG KHÔNG MONG MUỐN CỦA PHÁC ĐỒ EOX TRONG ĐIỀU TRỊ UNG THƯ DẠ DÀY Ở NGƯỜI CAO TUỔI

Abstract

Objectives: to evaluate the side effects of EOX regimen  of treating gastric cancer in elderly patients after radical surgery. Subjects and methods: Non-controlled clinical interventional study with vertical follow-up, with a combination of prospective and retrospective study was conducted on 57 elderly patients diagnosed with gastric cancer staged IIa – IIIc and undergoing surgical treatment at K Hospital and E hospital from January, 2009 to December, 2019. Results: The mean age of the subjects in the study was 63.7 ± 3.4 years old, with a male/female ratio of 3/1. Pre-existing diseases were hypertension (15.8%), gastric ulcers (12.3%), kidney or urinary tract diseases (12.3%), diabetes (10.5%). The overall side effects on hematology was mainly at grade 1, including 1.5% leukopenia, 2.6% grade 3- 4 agranulocytosis and 0.4% grade 4 thrombocytopenia ; The overall side effects on liver and kidney function was mainly at grade 1, of which the highest was the increase in SGOT (29.3%) and SGPT (20.2%); The overall clinical side effects was mainly at grade 1, but there were 3.2% episodes of vomiting grade 3-4, 1.5% diarrhea grade 3-4, 2.6% anorexia grade 3-4 and 05 patients with poor tolerance who had to change to Xelox regimen instead. Conclusions: Adjuvant chemotherapy EOX is an option for high-risk gastric cancer patients with radical surgery.